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present work aims to obtain clinical and analytical data that can guide us to an 
etiological diagnosis.
Objectives: To describe and identify the differences between HPS secondary 
to AID and HOD during their admission to a tertiary hospital between 2005 
and 2019.
Methods: This is a retrospective observational study. We include patient meet-
ing the diagnostic criteria for HLH proposed by Henter JI. (1), or who presented 
haemophagocytic cells (HC) in the bone marrow biopsy (BMB), or who had 
HPS in the hospital discharge report. Demographic, clinical, analytical, etiolog-
ical, underlying disorders and prognosis variables were collected. Continuous 
variables are described with the mean or median according to the degree of 
normality. Kruskal Wallis, Fisher test and Mann-Whitney U test were used for 
the bivariate analysis, and also a multivariate logistic regression analysis was 
performed.
Results: We found 30 patients with secondary HPS, 22 of which corresponded 
to the AID [Systemic Lupus Erythematosus (n=5), Adult Still’s Disease (n=3), 
Rheumatoid arthritis (n=1) and IgG4 Sclerosing Disease (n=1)] and HOD 
[Non-Hodgkin’s Lymphoma (n=3), Myelodysplastic syndrome (n=3), Acute leu-
kemia (n=3), Extranodal NK cell lymphoma (n=1), Multiple Myeloma (n=1) and 
probable lymphoproliferative process (n=1)]. The coincidence of an infectious 
disease with HPS was observed in 8 of the 22 cases [AID: 5 cases (2 Cytomeg-
alovirus, 2 viral respiratory infections and 1 bacterial infection) and HOD: 3 cases 
(2 Epstein Barr virus and 1 bacterial infection)]. In two patients with HPS sec-
ondary to HOD (acute leukemia), allogeneic transplantation was associated as 
a possible trigger. In a patient with myelodysplastic syndrome, HPS was associ-
ated with the development of graft versus host disease. The age at diagnosis was 
lower in the AID [40 (26.5 - 56.3); p 0.001]. The HOD had more severe cytopenias 
[platelets 4500 (650 - 15,750; p 0.009), leukocytes 2050 (20 - 728; p 0.0001) and 
neutrophils 0 (0 - 280; p 0.002)]. Overall mortality (n=30 patients) was 43.3% 
(HOD: 66.7%; p 0.029) (table 1). In the final multivariate model according to AID 
and HOD, the following independent associations were observed: age (p 0.002), 
platelets (p 0.031), GOT (p 0.012), GPT (p 0.015), total proteins (p 0.007) and 
mortality (p 0.007).
Conclusion: The HOD presented higher mortality and severe cytopenias. The 
AID presented a higher elevation of transaminases and better prognosis.
References: 
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Background: Ultra-rare genetically defined IL-1 mediated autoinflammatory 
diseases (AIDs) include mevalonate kinase deficiency (MKD), tumor necro-
sis factor receptor associated periodic syndrome (TRAPS), cryopyrinopathies 
(CAPS) and deficiency of the IL-1 receptor antagonist (DIRA). These disorders 
start perinatally, the clinical disease manifestations include systemic inflamma-
tion; and late diagnosis and inappropriate treatment cause irreversible organ 
damage. The varying skills of treating rheumatologists and paediatricians 
illustrate the need for management guidance, however criteria for validated 
methodology is geared towards common diseases with more heterogeneous 
pathogenesis.
Objectives: The focus of this systematic review includes the evaluation of the 
existing literature and the evaluation of existing EULAR methodology for use 
in the ultra-rare diseases with defined pathomechanisms, CAPS, TRAPS, MKD 
and DIRA
Methods: EULAR standardized operating procedures were followed during the 
review, including a meeting of experts to discuss key words, inclusion/exclusion 
criteria and PICO questions. Three fellows established the protocol of the review 
under the supervision of the EULAR methodologist and PubMed, Embase, and 
Cochrane databases were searched up to September 30, 2019.
Results: We found 1582 articles for CAPS, 1109 articles for TRAPS,1741 articles 
for MKD and 557 articles for DIRA. Duplications, animal models and basic sci-
ence studies, conference papers, systematic reviews/meta-analysis and articles 
not in English language is excluded. If we excluded case reports (n<4), then 72 
articles for CAPS, 40 articles for TRAPS,44 articles for MKD and 1 article for 
DIRA should be included for full text evaluation and data extraction (Figure 1). 
However among the case reports, patients excluded achieved complete remis-
sion, assessed by clinical criteria and biomarkers. Of the studies included only 
few randomized studies for CAPS, TRAPS, MKD, and DIRA and would achieve 
higher level of evidence (Figure 1).
Conclusion: CAPS, TRAPS, MKD and DIRA are monogenic diseases with 
defined pathways and outcomes that include inflammatory remission based 
on clinical and biomarker data. Current methodological evaluations for 
genetically complex diseases undervalue the published evidence in case 
reports that report on remission and IL-1 biomarkers. We suggest that case 
studies that include hard outcomes including inflammatory remission, and 
open label withdrawal studies that are both backed by biomarkers could 
be allowed to be included and be considered for a stronger evidence 
level.
Table 1. Characteristics and comparative analysis of HPS secondary to AID and HOD
 Total AID HOD
n 30 10 12 *p<0,05
Age (x ± s) 55,5 ±18,3 40 26,5-56,3 68 57,5-73,8 0,001
Gender, male 14 46,7% 3 30% 9 75% 0,084
Spenomegaly 16 53,3% 5 50% 8 66,7% 0,666
Hepatomegaly 10 33,3% 4 40% 4 33,3% 1,000
Hb (g/dL) 7,1 6,4-7,9 7,2 6,6-8,4 6,5 5,9-7,3 0,05
Pt (x109/L) 13 500 5 000-52 
500
31 650 11 000-100 
250
4 500 650-15 750 0,004
Leu (x109/L) 1 250 238-3 153 1 985 1 350-3 382 185 20 – 728 0,000
Neu (x109/L) 615 0-1 550 948 633-1 808 0 0-280 0,001
Fb (mg/dL) (n=24) 171 111-358 212 90-450 167 114-354 1,00
Fer (ng/mL) (n=28) 15 330 5 434-38 
284
14 263 4 254-14 263 16 796 8 287 - 56 
969
0,314
Tg (mmol/L) 341 226-438 411,5 234-572 321 233,8-403,8 0,314
GOT (U/L) 139 78-406 457 289-1 140 106 71-193 0,003
GPT (U/L) 162 46-388 432 174-599 109 54-263 0,017
T.P. (n=29) 4,8 ±,1,04 5,0 4,5-5,8 4,3 3,9-4,5 0,003
Hospital stay 35,5 20,0-60,8 30,5 9,5-53,3 61,5 29,3-93,3 0,036
Hospital stay pre-dx 16,5 8,5-29,8 10 5,0-16,5 26 10-39 0,038
Mortality 13 43,3% 1 10% 8 66,7% 0,011
Hb: hemoglobin, Pt: platelets, Leu; leukocytes, Neu, neutrophils, Fb: fibrinogen, Fer: ferritin, Tg: triglycerides, GOT: aspartate aminotransferase, GPT: alanine aminotransferase, T.P.: total proteins, 
pre-dx: prior to the diagnosis of HPS according to BMO. *Analysis between AID and HOD.
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Background: Familial Mediterranean Fever (FMF), which is more common in 
groups in the Mediterranean basin, is a monogenic autoinflammatory disease 
characterized by recurrent attacks of febrile peritonitis, pleuritis and arthritis.
Objectives: In this study, we aimed to investigate the clinical, demographic and 
genotypic features that may be associated with subclinical inflammation in FMF 
and to determine the related parameters with subclinical inflammation.
Methods: FMF patients according to the Tel-Hashomer criteria were included 
into the study. The demographic characteristics of the patients, duration of 
the disease, concomitant diseases, MEFV genotype mutation, colchicine use 
and resistance were collected. Acute-phase reactants such as white blood cell 
count, erythrocyte sedimentation rate, and C-reactive protein levels during 
the attacks and attack-free periods were noted. Subclinical inflammation was 
defined as the continuation of the acute phase response (CRP) between epi-
sodes. We divided study population into two groups as; patients with or without 
subclinical inflammation (Group 1 and Group 2, respectively) and these group 
were compared with the parameters described above. Patients with infectious 
disease (viral or bacterial) in the past two months were excluded from the 
study
Results: Eigthy patients (72.5% female) with mean age 37.1 SD 11.2 years 
were recruited into the study. Twenty-three (28.7%) patients were determined 
with subclinical inflammation. Group 1 had significantly higher rate of concomi-
tant rheumatic disease(i.e spondyloarthropathy), erythrocyte sedimentation rate 
and MEFV homozygous mutation compared with Group 2 (p<0.05, for each). 
Disease duration, months PRASS score, FMF quality of life, age at onset of 
symptoms, family history of FMF, response to colchicine, attack time, attack in 
the last 6, delay in diagnosis parameters were not significantly different between 
groups (p> 0.05).
Conclusion: FMF patients whose elevated erythrocyte sedimentation rate and 
MEFV homozygous mutation should be closely monitored for subclinical inflam-
mation even during attack-free periods. Concomitant disease should be detected 
in FMF patients with subclinical inflammation.
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Table 1: Demographic and clinical features of the patients with familial 
Mediterranean fever








Age (years; mean SD) 37,78 SD 13,22 36,82 SD 10,49 0.987
Female, gender, n (%) 45(%78) 13(%56) 0.055
Disease duration
(month; mean SD)
255,3 SD 195,1 180,2 SD 121,1 0.191
PRASS score
(mean SD)
6,08 SD 2,15 5,36 SD 1,59 0.147
BMİ, kg/m2 26,12 SD 4,8 32,13 SD 28,48 0.629
Current smoking status (%) 17(%29) 3(%13) 0.067
Age at onset of symptoms (month;  
mean SD)
15,69 SD 9,41 17,28 SD 10,34 0.54
Family history of FMF(%) 37(%64) 18(%78) 0.295
Response to colchicine(%) 6(%10) 4(%17) 0.462
Attack time
(day; mean SD)
1,9 SD 1,1 2,26 SD 1,4 0,523
Attack in the last 6 months (mean SD) 2,79 SD 3,1 4,56 SD 5,5 0,184
FMF quality of life
(mean SD)
31,5 SD 13,6 25.7 SD 16,4 0,130
Delay in diagnosis(month; mean SD) 12,29 SD 10,9 14,3 SD 14,9 0,840
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Background: Erdheim-Chester disease (ECD) is a rare non-Langerhans histio-
cytosis. Combined treatment with anakinra (ANK) and targeted MAPK-inhibiting 
therapies (vemurafenib – VMF - or cobimetinib - CBM) has been recently used to 
treat severe cases of ECD.
Objectives: To evaluate the safety and the clinical and radiological efficacy 
of ANK, targeted and combined treatments in ECD patients in a real-world 
setting.
Figure 1. Flow-charts of systematic review for CAPS, TRAPS and MKD.
Table 1. Disease characteristics and therapy-related adverse reactions 
of Erdheim-Chester patients treated with vemurafenib, cobimetinib and/
or anakinra.
 Vemurafenib (n=19) Cobimetinib (n=10) Anakinra (n=12)
Clinical Manifestations    
 Cardiovascular 79% 70% 75%
 Retroperitoneal 84% 60% 42%
 Pleuropulmonary 63% 80% 42%
 Neurological and/or orbital 90% 90% 92%
Adverse reactions 74% 60% 25%
 Renal 26% 10% 0%
 Cutaneous 26% 30% 17%
 Systemic Inflammation 11% 10% 0%
 Cardiovascular 11% 10% 0%
 Gastrointestinal 0% 30% 0%
 Haematological 0% 10% 0%
 Herpes Zoster 0% 0% 8%
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